pacritinib

Known as: Oral JAK2 Inhibitor SB1518 
An orally bioavailable inhibitor of Janus kinase 2 (JAK2) and the JAK2 mutant JAK2V617F with potential antineoplastic activity. Oral JAK2 inhibitor… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2011-2017
051020112017

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Pacritinib, potent inhibitor of Janus kinase 2 (JAK2), JAK2V617F, and fms-like receptor tyrosine kinase 3, is in Phase III… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?
2016
2016
BACKGROUND Pacritinib (SB1518) is a highly selective kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CFS1R. This… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 4
Is this relevant?
Review
2016
Review
2016
INTRODUCTION Dysregulation of janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway has been… (More)
Is this relevant?
2015
2015
Pacritinib (SB1518) is a Janus kinase 2 (JAK2), JAK2(V617F), and Fms-like tyrosine kinase 3 inhibitor that does not inhibit JAK1… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
  • figure 2
Is this relevant?
Review
2015
Review
2015
Myelofibrosis (MF) is a myeloid disorder caused by a clonal hematopoietic stem-cell proliferation associated with activation of… (More)
Is this relevant?
Review
2015
Review
2015
The first-in-class JAK1/JAK2 inhibitor ruxolitinib inhibits JAK/STAT signaling, inducing durable reductions in splenomegaly and… (More)
Is this relevant?
Review
2015
Review
2015
INTRODUCTION Myelofibrosis (MF) is a clonal haematological disease associated with recurrent somatic gene mutations (JAK2V617F… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
2014
2014
The recent discovery of the JAK2 mutation and its role in the pathogenesis of myeloproliferative neoplasms led to the development… (More)
  • figure 1
  • table 1
Is this relevant?
2012
2012
Acute myeloid leukemia (AML) is currently treated with aggressive chemotherapy that is not well tolerated in many elderly… (More)
Is this relevant?
2011
2011
FMS-like tyrosine kinase 3 (FLT3) is the most commonly mutated gene found in acute myeloid leukemia (AML) patients and its… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?